The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
…, Y Park, CE Edwards, E Weimer, EM Scherer… - Science …, 2020 - science.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in
late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this …
late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this …
[PDF][PDF] Rapid generation of neutralizing antibody responses in COVID-19 patients
…, N Saakadze, GH Smith, S Edupuganti, EM Scherer… - Cell Reports …, 2020 - cell.com
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide
pandemic, and there is a pressing need to understand the development, specificity, and …
pandemic, and there is a pressing need to understand the development, specificity, and …
[HTML][HTML] SARS-CoV-2 evolution and immune escape in immunocompromised patients
EM Scherer, A Babiker, MW Adelman… - … England Journal of …, 2022 - Mass Medical Soc
… M. Tsuboi et al. … Stephanie M. Pouch, MD … Rouphael and Scherer) from the National
Institutes of Health ( NIH ); by a Simons Foundation Investigator Award in the Mathematical …
Institutes of Health ( NIH ); by a Simons Foundation Investigator Award in the Mathematical …
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
…, T Lambe, M Puthia, C Svanborg, EM Scherer… - Nature …, 2012 - nature.com
Protection against mucosally transmitted infections probably requires immunity at the site of
pathogen entry 1, yet there are no mucosal adjuvant formulations licensed for human use. …
pathogen entry 1, yet there are no mucosal adjuvant formulations licensed for human use. …
Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions
EM Scherer, DP Leaman, MB Zwick… - Proceedings of the …, 2010 - National Acad Sciences
The broadly neutralizing anti-HIV antibody 4E10 recognizes an epitope very close to the
virus membrane on the glycoprotein gp41. It was previously shown that epitope recognition …
virus membrane on the glycoprotein gp41. It was previously shown that epitope recognition …
[HTML][HTML] Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity
EM Scherer, RA Smith, CA Simonich… - PLoS …, 2014 - journals.plos.org
Licensed human papillomavirus (HPV) vaccines provide near complete protection against
the types of HPV that most commonly cause anogenital and oropharyngeal cancers (HPV 16 …
the types of HPV that most commonly cause anogenital and oropharyngeal cancers (HPV 16 …
[HTML][HTML] A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects
Although licensed human papillomavirus (HPV) vaccines are most efficacious in persons never
infected with HPV, they also reduce infection and disease in previously infected subjects, …
infected with HPV, they also reduce infection and disease in previously infected subjects, …
The RBD of the Spike Protein of SARS-Group Coronaviruses is a highly specific target of SARS-CoV-2 antibodies but not other pathogenic human and animal …
A new Severe Acute Respiratory Syndrome Coronavirus variant (SARS-CoV-2) that first
emerged in late 2019 is responsible for a pandemic of severe respiratory illness. People …
emerged in late 2019 is responsible for a pandemic of severe respiratory illness. People …
Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity
EM Scherer, MB Zwick, L Teyton, DR Burton - Aids, 2007 - journals.lww.com
Objective: In a recent report [Haynes et al. Science 2005; 308: 1906–1908], difficulties in
eliciting broadly neutralizing antibodies to HIV were linked to the binding of prototypic broadly …
eliciting broadly neutralizing antibodies to HIV were linked to the binding of prototypic broadly …
[HTML][HTML] Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns
…, G Krashias, F Wegmann, WR Hillson, EM Scherer… - Vaccine, 2016 - Elsevier
Carbopol is a polyanionic carbomer used in man for topical application and drug delivery
purposes. However parenteral administration of Carbopol in animal models results in systemic …
purposes. However parenteral administration of Carbopol in animal models results in systemic …
